Rong Wang, PhD

• Alyssa Ann Grimshaw
• Amer Zeidan
• Anees Chagpar
• Brian Leaderer
• Cary Gross
• Cassandra Clark
• Darrick K. Li
• Dhanpat Jain
• Henry S. Park
• Jeph Herrin
• Joseph Ross
• Kenneth B. Roberts
• Lourdes Mendez
• Michael S. Leapman
• Michaela Dinan
• Natalia Neparidze
• Nicole Deziel
• Nikolai Podoltsev
• Pamela L. Kunz
• Prasanna Ananth
• Rory Shallis
• Rozalyn Levine Rodwin
• Scott Huntington
• Shalin Kothari
• Shi-Yi Wang
• Stephanie Halene
• Stephanie Prozora
• Stuart Seropian
• Tarsheen Sethi
• Theodore Holford
• Tormod Rogne
• Xiao Xu
• Xiaomei Ma

Chronic Disease; Epidemiology; Neoplasms; Biostatistics; Health Care

Cancer; Environmental Health; Maternal & Child Health

• Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemiaPodoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.
• Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherenceShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.
• Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015Cote D, Wang R, Morimoto L, Metayer C, Zada G, Wiemels J, Ma X. Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015. Cancer Causes & Control 2023, 34: 757-768. PMID: 37225897, PMCID: PMC10363066, DOI: 10.1007/s10552-023-01718-7.
• Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyureaWang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.
• Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With ObservationLeapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.
• Outdoor artificial light at night, air pollution, and risk of childhood acute lymphoblastic leukemia in the California Linkage Study of Early-Onset CancersZhong C, Wang R, Morimoto L, Longcore T, Franklin M, Rogne T, Metayer C, Wiemels J, Ma X. Outdoor artificial light at night, air pollution, and risk of childhood acute lymphoblastic leukemia in the California Linkage Study of Early-Onset Cancers. Scientific Reports 2023, 13: 583. PMID: 36631468, PMCID: PMC9834257, DOI: 10.1038/s41598-022-23682-z.
• Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic periodNeparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.
• Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALLFeng Q, Zhou M, Li S, Morimoto L, Hansen H, Myint SS, Wang R, Metayer C, Kang A, Fear AL, Pappas D, Erlich H, Hollenbach JA, Mancuso N, Trachtenberg E, de Smith AJ, Ma X, Wiemels JL. Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances 2022, 6: 3756-3766. PMID: 35500222, PMCID: PMC9631572, DOI: 10.1182/bloodadvances.2021006821.
• Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control StudyGraham C, Metayer C, Morimoto LM, Wiemels JL, Siddique A, Di M, Rodwin RL, Kadan-Lottick NS, Ma X, Wang R. Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 1788-1795. PMID: 35709749, PMCID: PMC9444874, DOI: 10.1158/1055-9965.epi-22-0335.
• Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysisDi M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.
• Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
• Cytomegalovirus proteins, maternal pregnancy cytokines, and their impact on neonatal immune cytokine profiles and acute lymphoblastic leukemogenesis in children.Wiemels JL, Wang R, Zhou M, Hansen H, Gallant R, Jung J, Mancuso N, De Smith AJ, Metayer C, Kogan SC, Ma X. Cytomegalovirus proteins, maternal pregnancy cytokines, and their impact on neonatal immune cytokine profiles and acute lymphoblastic leukemogenesis in children. Haematologica 2022, 107: 2266-2270. PMID: 35638549, PMCID: PMC9425315, DOI: 10.3324/haematol.2022.280826.
• Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control StudyLam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.
• Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic LeukemiaRodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.
• The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysisGoksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia & Lymphoma 2022, 63: 1651-1659. PMID: 35133215, DOI: 10.1080/10428194.2022.2032034.
• Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United StatesBewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
• Birth characteristics and risk of meningioma in a population-based study in CaliforniaCote D, Wang R, Morimoto L, Metayer C, Stempel J, Zada G, Ma X, Wiemels J. Birth characteristics and risk of meningioma in a population-based study in California. Neuro-Oncology Advances 2022, 4: vdac173. PMID: 36479059, PMCID: PMC9721385, DOI: 10.1093/noajnl/vdac173.
• Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer ScreeningLeapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.
• Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control StudyDwyer KE, Wang R, Cozen W, Cartmel B, Wiemels JL, Morimoto LM, Metayer C, Ma X. Mode of Delivery, Birth Characteristics and Early-Onset Non-Hodgkin Lymphoma in a Population-Based Case-Control Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: cebp.0535.2021. PMID: 34548330, DOI: 10.1158/1055-9965.epi-21-0535.
• Proximity to endocrine-disrupting pesticides and risk of testicular germ cell tumors (TGCT) among adolescents: A population-based case-control study in CaliforniaSwartz SJ, Morimoto LM, Whitehead TP, DeRouen MC, Ma X, Wang R, Wiemels JL, McGlynn KA, Gunier R, Metayer C. Proximity to endocrine-disrupting pesticides and risk of testicular germ cell tumors (TGCT) among adolescents: A population-based case-control study in California. International Journal Of Hygiene And Environmental Health 2021, 239: 113881. PMID: 34839102, DOI: 10.1016/j.ijheh.2021.113881.
• Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisDi M, Cui C, Kothari S, Zeidan A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. Blood 2021, 138: 182. DOI: 10.1182/blood-2021-146417.
• Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodNeparidze N, Wang R, Zeidan A, Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. Blood 2021, 138: 4092. PMCID: PMC8701553, DOI: 10.1182/blood-2021-148998.
• Contemporary “Real World” Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary “Real World” Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States. Blood 2021, 138: 282. DOI: 10.1182/blood-2021-151066.
• Physical Therapy Utilization Among Hospitalized Patients with Pediatric Acute Lymphoblastic LeukemiaRodwin R, Ma X, Ness K, Kadan-Lottick N, Wang R. Physical Therapy Utilization Among Hospitalized Patients with Pediatric Acute Lymphoblastic Leukemia. Blood 2021, 138: 4024. DOI: 10.1182/blood-2021-147232.
• Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer ManagementLeapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.
• Outdoor artificial light at night, air pollution, and childhood acute lymphoblastic leukemiaZhong C, Wang R, Morimoto L, Longcore T, Chau K, Franklin M, Metayer C, Wiemels J, Ma X. Outdoor artificial light at night, air pollution, and childhood acute lymphoblastic leukemia. ISEE Conference Abstracts 2021, 2021 DOI: 10.1289/isee.2021.o-lt-039.
• Sociodemographic and hospital‐based predictors of intense end‐of‐life care among children, adolescents, and young adults with hematologic malignanciesMun S, Wang R, Ma X, Ananth P. Sociodemographic and hospital‐based predictors of intense end‐of‐life care among children, adolescents, and young adults with hematologic malignancies. Cancer 2021, 127: 3817-3824. PMID: 34185881, PMCID: PMC8478813, DOI: 10.1002/cncr.33764.
• Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic LeukemiaWhitehead TP, Wiemels JL, Zhou M, Kang AY, McCoy LS, Wang R, Fitch B, Petrick LM, Yano Y, Imani P, Rappaport SM, Dahl GV, Kogan SC, Ma X, Metayer C. Cytokine Levels at Birth in Children Who Developed Acute Lymphoblastic Leukemia. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1526-1535. PMID: 34078642, PMCID: PMC8338848, DOI: 10.1158/1055-9965.epi-20-1704.
• Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United StatesWang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.
• Patterns of Care for Older Patients With Myelofibrosis: A Population-based StudyMeckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care for Older Patients With Myelofibrosis: A Population-based Study. Clinical Lymphoma Myeloma & Leukemia 2021, 21: e551-e558. PMID: 33648884, DOI: 10.1016/j.clml.2021.01.025.
• Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative NeoplasmsShallis RM, Zeidan AM, Wang R, Podoltsev NA. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Hematology/Oncology Clinics Of North America 2021, 35: 177-189. PMID: 33641862, DOI: 10.1016/j.hoc.2020.11.005.
• Regional Adoption of Commercial Gene Expression Testing for Prostate CancerLeapman MS, Wang R, Ma S, Gross CP, Ma X. Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer. JAMA Oncology 2021, 7: 52-58. PMID: 33237277, PMCID: PMC7689565, DOI: 10.1001/jamaoncol.2020.6086.
• Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United StatesShallis RM, Wang R, Bewersdorf JP, Zeidan AM, Davidoff AJ, Huntington SF, Podoltsev NA, Ma X. Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic Advances In Hematology 2021, 12: 20406207211043404. PMID: 35154624, PMCID: PMC8832334, DOI: 10.1177/20406207211043404.
• Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based StudyMeckstroth S, Wang R, Ma X, Podoltsev N. Patterns of Care and Outcomes Among Older Patients with Myelofibrosis: A Population-Based Study. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-137543.
• Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic LeukemiaBewersdorf J, Prozora S, Wang R, Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-136983.
• Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesWang R, Shallis R, Bewersdorf J, Zeidan A, Huntington S, Ma X, Podoltsev N. Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood 2020, 136: 13-14. DOI: 10.1182/blood-2020-139468.
• Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Bewersdorf J, Zeidan A, Huntington S, Davidoff A, Ma X, Podoltsev N. Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood 2020, 136: 44-45. DOI: 10.1182/blood-2020-139531.
• Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and OutcomesDavidoff A, Long J, Neparidze N, Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140728.
• Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based StudyGoksu S, Khatib J, Goksu B, Wang R, Patel P, Vusirkala M, Cole S, Seyhanli A, Ozer M, Collins R, Chung S, Zeidan A, Madanat Y. Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140564.
• Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP CohortPodoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa RA, Ma X. Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 2343-2350. PMID: 32868318, PMCID: PMC8895351, DOI: 10.1158/1055-9965.epi-20-0592.
• Socioeconomic status and childhood central nervous system tumors in CaliforniaFrancis SS, Wang R, Enders C, Prado I, Wiemels JL, Ma X, Metayer C. Socioeconomic status and childhood central nervous system tumors in California. Cancer Causes & Control 2020, 32: 27-39. PMID: 33113073, DOI: 10.1007/s10552-020-01348-3.
• Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in CaliforniaDeziel N, Zhang Y, Wang R, Wiemels JL, Morimoto L, Clark CJ, Metayer C, Ma X. Birth Characteristics and Risk of Pediatric Thyroid Cancer: A Population-Based Record-Linkage Study in California. Thyroid 2020, 31: 596-606. PMID: 32912083, PMCID: PMC8195873, DOI: 10.1089/thy.2020.0217.
• Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysisBewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysis. Leukemia 2020, 35: 1643-1660. PMID: 32868875, PMCID: PMC7917159, DOI: 10.1038/s41375-020-01020-4.
• Birth Characteristics and Risk of Early-Onset Synovial SarcomaWiemels JL, Wang R, Feng Q, Clark CJ, Amatruda JF, Rubin E, Yee AC, Morimoto LM, Metayer C, Ma X. Birth Characteristics and Risk of Early-Onset Synovial Sarcoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 1162-1167. PMID: 32245786, PMCID: PMC7605594, DOI: 10.1158/1055-9965.epi-20-0093.
• Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysisBewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clinical Lymphoma Myeloma & Leukemia 2020, 20: e712-e723. PMID: 32669244, PMCID: PMC7541411, DOI: 10.1016/j.clml.2020.05.018.
• Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agentsGiri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.
• Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex mapShallis RM, Wang R, Davidoff A, Ma X, Podoltsev NA, Zeidan AM. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. Blood Reviews 2020, 42: 100706. PMID: 32517877, DOI: 10.1016/j.blre.2020.100706.
• Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. DOI: 10.1200/jco.2020.38.15_suppl.e19057.
• Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United StatesZeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
• Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesZeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
• Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumptionPodoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Reply to comments on: Lifestyles and myeloproliferative neoplasms with special reference to coffee consumption. International Journal Of Cancer 2020, 146: 3523-3523. PMID: 32167580, PMCID: PMC8915778, DOI: 10.1002/ijc.32974.
• Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysisKaralexi MA, Dessypris N, Ma X, Spector LG, Marcotte E, Clavel J, Pombo-de-Oliveira MS, Heck JE, Roman E, Mueller BA, Hansen J, Auvinen A, Lee PC, Schüz J, Magnani C, Mora AM, Dockerty JD, Scheurer ME, Wang R, Bonaventure A, Kane E, Doody DR, Group N, Baka M, Moschovi M, Polychronopoulou S, Kourti M, Hatzipantelis E, Pelagiadis I, Dana H, Kantzanou M, Tzanoudaki M, Anastasiou T, Grenzelia M, Gavriilaki E, Sakellari I, Anagnostopoulos A, Kitra V, Paisiou A, Bouka E, Group F, Nikkilä A, Lohi O, Erdmann F, Kang A, Metayer C, Milne E, Petridou E. Age-, sex- and disease subtype–related foetal growth differentials in childhood acute myeloid leukaemia risk: A Childhood Leukemia International Consortium analysis. European Journal Of Cancer 2020, 130: 1-11. PMID: 32163883, DOI: 10.1016/j.ejca.2020.01.018.
• Spatial-Temporal Cluster Analysis of Childhood Cancer in California.Francis SS, Enders C, Hyde R, Gao X, Wang R, Ma X, Wiemels JL, Selvin S, Metayer C. Spatial-Temporal Cluster Analysis of Childhood Cancer in California. Epidemiology 2020, 31: 214-223. PMID: 31596791, PMCID: PMC9005107, DOI: 10.1097/ede.0000000000001121.
• Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health studyPodoltsev NA, Wang X, Wang R, Hofmann JN, Liao LM, Zeidan AM, Mesa R, Ma X. Lifestyle factors and risk of myeloproliferative neoplasms in the NIH‐AARP diet and health study. International Journal Of Cancer 2020, 147: 948-957. PMID: 31904114, PMCID: PMC8919268, DOI: 10.1002/ijc.32853.
• Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysisBewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 2020, 105: 2659-2663. PMID: 33131256, PMCID: PMC7604631, DOI: 10.3324/haematol.2019.242826.
• Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.
• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential ThrombocythemiaPodoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 2019, 134: 2125. DOI: 10.1182/blood-2019-127563.
• Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748. DOI: 10.1182/blood-2019-128821.
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based StudyZeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study. Blood 2019, 134: 116. DOI: 10.1182/blood-2019-126643.
• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United StatesZeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood 2019, 134: 646. DOI: 10.1182/blood-2019-127398.
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with HydroxyureaWang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea. Blood 2019, 134: 330. DOI: 10.1182/blood-2019-127568.
• Immunoepidemiology of CancerMa X, Wang R. Immunoepidemiology of Cancer. 2019, 215-224. DOI: 10.1007/978-3-030-25553-4_13.
• Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.
• Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysisZeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis. Cancer 2019, 125: 4241-4251. PMID: 31483484, PMCID: PMC7733320, DOI: 10.1002/cncr.32439.
• Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
• Healthcare expenses for treatment of acute myeloid leukemiaBewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.
• Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
• Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiologyNielsen AB, Zhou M, de Smith AJ, Wang R, McCoy L, Hansen H, Morimoto L, Grønbæk K, Johansen C, Kogan SC, Metayer C, Bracci PM, Ma X, Wiemels JL. Increased neonatal level of arginase 2 in cases of childhood acute lymphoblastic leukemia implicates immunosuppression in the etiology. Haematologica 2019, 104: e514-e516. PMID: 30923090, PMCID: PMC6821599, DOI: 10.3324/haematol.2019.216465.
• Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study. Blood 2018, 132: 4865. DOI: 10.1182/blood-2018-99-119118.
• Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580. DOI: 10.1182/blood-2018-99-119272.
• Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood 2018, 132: 978. DOI: 10.1182/blood-2018-99-119791.
• Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based AnalysisZeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370. DOI: 10.1182/blood-2018-99-111052.
• Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET UtilityHuntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood 2018, 132: 3538. DOI: 10.1182/blood-2018-99-115140.
• Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) TransfusionsZeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838. DOI: 10.1182/blood-2018-99-116497.
• Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of LifeWang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology 2017, 35: jco.2017.72.714. PMID: 28783450, PMCID: PMC5648174, DOI: 10.1200/jco.2017.72.7149.
• Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in CaliforniaWang R, Metayer C, Morimoto L, Wiemels JL, Yang J, DeWan AT, Kang A, Ma X. Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California. American Journal Of Epidemiology 2017, 186: 843-856. PMID: 28535175, PMCID: PMC5860074, DOI: 10.1093/aje/kwx160.
• Physician volume and discontinuation of rituximab during lymphoma treatment.Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.
• Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.
• 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.
• 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s20-s21. DOI: 10.1016/s0145-2126(17)30145-5.
• Cesarean Section and Risk of Childhood Acute Lymphoblastic Leukemia in a Population-Based, Record-Linkage Study in CaliforniaWang R, Wiemels JL, Metayer C, Morimoto L, Francis SS, Kadan-Lottick N, DeWan AT, Zhang Y, Ma X. Cesarean Section and Risk of Childhood Acute Lymphoblastic Leukemia in a Population-Based, Record-Linkage Study in California. American Journal Of Epidemiology 2016, 185: 96-105. PMID: 27986703, PMCID: PMC5253971, DOI: 10.1093/aje/kww153.
• Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell RescueHui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188. DOI: 10.1182/blood.v128.22.1188.1188.
• Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.
• Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based StudyWang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.
• Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873. DOI: 10.1182/blood.v126.23.873.873.
• Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based StudyWang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.
• Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based StudyZeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. Blood 2015, 126: 1676. DOI: 10.1182/blood.v126.23.1676.1676.
• Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.
• Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes (MDS). Clinical Lymphoma Myeloma & Leukemia 2015, 15: s44-s45. DOI: 10.1016/j.clml.2015.07.094.
• Disease Risk Estimation by Combining Case–Control Data with Aggregated Information on the Population at RiskChang X, Waagepetersen R, Yu H, Ma X, Holford TR, Wang R, Guan Y. Disease Risk Estimation by Combining Case–Control Data with Aggregated Information on the Population at Risk. Biometrics 2014, 71: 114-121. PMID: 25351292, PMCID: PMC4782587, DOI: 10.1111/biom.12256.
• Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer CareWang SY, Wang R, Yu JB, Ma X, Xu X, Kim SP, Soulos PR, Saraf A, Gross CP. Understanding Regional Variation in Medicare Expenditures for Initial Episodes of Prostate Cancer Care. Medical Care 2014, 52: 680-687. PMID: 25023913, PMCID: PMC4129645, DOI: 10.1097/mlr.0000000000000158.
• Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic ImplicationsKillelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS, Gross CP. Evolution of Breast Cancer Screening in the Medicare Population: Clinical and Economic Implications. Journal Of The National Cancer Institute 2014, 106 PMID: 25031307, PMCID: PMC4155428, DOI: 10.1093/jnci/dju159.
• Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancerXu X, Soulos P, Herrin J, Ross J, Saraf A, Roberts K, Killelea B, Wang S, Long J, Wang R, Ma X, Gross C. Abstract P6-07-05: Regional variation in Medicare expenditures for older women with localized breast cancer. Cancer Research 2013, 73: p6-07-05-p6-07-05. DOI: 10.1158/0008-5472.sabcs13-p6-07-05.
• The cost implications of prostate cancer screening in the Medicare populationMa X, Wang R, Long JB, Ross JS, Soulos PR, Yu JB, Makarov DV, Gold HT, Gross CP. The cost implications of prostate cancer screening in the Medicare population. Cancer 2013, 120: 96-102. PMID: 24122801, PMCID: PMC3867600, DOI: 10.1002/cncr.28373.
• The cost implications of prostate cancer screening in the Medicare population.Ma X, Wang R, Long J, Ross J, Soulos P, Yu J, Makarov D, Gold H, Gross C. The cost implications of prostate cancer screening in the Medicare population. Journal Of Clinical Oncology 2013, 31: 6549-6549. DOI: 10.1200/jco.2013.31.15_suppl.6549.
• The Cost of Breast Cancer Screening in the Medicare PopulationGross CP, Long JB, Ross JS, Abu-Khalaf MM, Wang R, Killelea BK, Gold HT, Chagpar AB, Ma X. The Cost of Breast Cancer Screening in the Medicare Population. JAMA Internal Medicine 2013, 173: 220-226. PMID: 23303200, PMCID: PMC3638736, DOI: 10.1001/jamainternmed.2013.1397.
• Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare BeneficiariesRoss JS, Wang R, Long JB, Gross CP, Ma X. Impact of the 2008 US Preventive Services Task Force Recommendation to Discontinue Prostate Cancer Screening Among Male Medicare Beneficiaries. JAMA Internal Medicine 2012, 172: 1601-1603. PMID: 22987029, PMCID: PMC3597450, DOI: 10.1001/archinternmed.2012.3726.
• The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromesWang R, Gross CP, Frick K, Xu X, Long J, Raza A, Galili N, Zikria J, Guan Y, Ma X. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leukemia Research 2012, 36: 1370-1375. PMID: 22917770, PMCID: PMC3458648, DOI: 10.1016/j.leukres.2012.07.020.
• Patterns of subsequent malignancies after Hodgkin lymphoma in children and adultsOmer B, Kadan‐Lottick N, Roberts KB, Wang R, Demsky C, Kupfer GM, Cooper D, Seropian S, Ma X. Patterns of subsequent malignancies after Hodgkin lymphoma in children and adults. British Journal Of Haematology 2012, 158: 615-625. PMID: 22775513, DOI: 10.1111/j.1365-2141.2012.09211.x.
• The evolution of breast cancer screening in the Medicare population: Clinical and economic implications.Killelea B, Long J, Ma X, Wang R, Chagpar A, Ross J, Gross C. The evolution of breast cancer screening in the Medicare population: Clinical and economic implications. Journal Of Clinical Oncology 2012, 30: 1595-1595. DOI: 10.1200/jco.2012.30.15_suppl.1595.
• Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes.Ma X, Wang R, Long J, Gold H, Halene S, Gross C. Regional variation in treatment costs and survival for elderly patients with myelodysplastic syndromes. Journal Of Clinical Oncology 2012, 30: 6628-6628. DOI: 10.1200/jco.2012.30.15_suppl.6628.
• Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromesMa X, Wang R, Galili N, Mayne ST, Wang SA, Yu H, Raza A. Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes. Cancer Causes & Control 2011, 22: 623-629. PMID: 21287258, PMCID: PMC3086405, DOI: 10.1007/s10552-011-9735-6.
• Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP CohortMa X, Park Y, Mayne ST, Wang R, Sinha R, Hollenbeck AR, Schatzkin A, Cross AJ. Diet, Lifestyle, and Acute Myeloid Leukemia in the NIH–AARP Cohort. American Journal Of Epidemiology 2009, 171: 312-322. PMID: 20042434, PMCID: PMC2842202, DOI: 10.1093/aje/kwp371.
• A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004Zhu C, Zheng T, Kilfoy BA, Han X, Ma S, Ba Y, Bai Y, Wang R, Zhu Y, Zhang Y. A Birth Cohort Analysis of the Incidence of Papillary Thyroid Cancer in the United States, 1973–2004. Thyroid 2009, 19: 1061-1066. PMID: 19732011, PMCID: PMC2833179, DOI: 10.1089/thy.2008.0342.
• Clarification on the categorization of comorbiditiesWang R, Ma X. Clarification on the categorization of comorbidities. Leukemia Research 2009, 34: e74. PMID: 19783302, PMCID: PMC2815216, DOI: 10.1016/j.leukres.2009.08.036.
• Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United StatesWang R, Gross CP, Halene S, Ma X. Neighborhood socioeconomic status influences the survival of elderly patients with myelodysplastic syndromes in the United States. Cancer Causes & Control 2009, 20: 1369-1376. PMID: 19455395, PMCID: PMC2921772, DOI: 10.1007/s10552-009-9362-7.
• Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US CohortMa X, Lim U, Park Y, Mayne ST, Wang R, Hartge P, Hollenbeck AR, Schatzkin A. Obesity, Lifestyle Factors, and Risk of Myelodysplastic Syndromes in a Large US Cohort. American Journal Of Epidemiology 2009, 169: 1492-1499. PMID: 19395696, PMCID: PMC2727203, DOI: 10.1093/aje/kwp074.
• Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromesWang R, Gross CP, Halene S, Ma X. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leukemia Research 2009, 33: 1594-1598. PMID: 19324411, PMCID: PMC2749891, DOI: 10.1016/j.leukres.2009.02.005.
• Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut WomenWang R, Zhang Y, Lan Q, Holford TR, Leaderer B, Zahm SH, Boyle P, Dosemeci M, Rothman N, Zhu Y, Qin Q, Zheng T. Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. American Journal Of Epidemiology 2008, 169: 176-185. PMID: 19056833, PMCID: PMC2727253, DOI: 10.1093/aje/kwn300.
• Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin LymphomaZhang Y, De Sanjose S, Bracci PM, Morton LM, Wang R, Brennan P, Hartge P, Boffetta P, Becker N, Maynadie M, Foretova L, Cocco P, Staines A, Holford T, Holly EA, Nieters A, Benavente Y, Bernstein L, Zahm SH, Zheng T. Personal Use of Hair Dye and the Risk of Certain Subtypes of Non-Hodgkin Lymphoma. American Journal Of Epidemiology 2008, 167: 1321-1331. PMID: 18408225, PMCID: PMC4025953, DOI: 10.1093/aje/kwn058.
• Exposure to Solvents and Risks for Non-Hodgkin's Lymphoma in Connecticut WomenWang R, Zhang Y, Lan Q, Holford T, Leaderer B, Zahm S, Dosemeci M, Rothman N, Boyle P, Zhu Y, Qin Q, Zheng T. Exposure to Solvents and Risks for Non-Hodgkin's Lymphoma in Connecticut Women. Annals Of Epidemiology 2007, 17: 724. DOI: 10.1016/j.annepidem.2007.07.009.
• Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's LymphomaZhang Y, Holford TR, Leaderer B, Boyle P, Zhu Y, Wang R, Zou K, Zhang B, Wise JP, Qin Q, Kilfoy B, Han J, Zheng T. Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. American Journal Of Epidemiology 2007, 165: 1255-1264. PMID: 17327216, DOI: 10.1093/aje/kwm020.
• Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphomaZhang Y, Wang R, Holford TR, Leaderer B, Zahm SH, Boyle P, Zhu Y, Qin Q, Zheng T. Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes & Control 2007, 18: 351-359. PMID: 17206533, DOI: 10.1007/s10552-006-0088-5.